Assessment Status | Rapid Review Complete |
HTA ID | 23009 |
Drug | Durvalumab |
Brand | Imfinzi® |
Indication | Durvalumab in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer. |
Assessment Process | |
Rapid review commissioned | 20/02/2023 |
Rapid review completed | 16/03/2023 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab used in combination with gemcitabine and cisplatin compared with the current SOC (gemcitabine and cisplatin). |